Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2011

View Archived Issues

Preclinical and first-in-human data presented on NDV-3 candidiasis vaccine

Recombinant measles vector-based HIV-1 vaccine evaluated in primates

Preliminary findings from IMPACT study made available

Riemser Arzneimittel receives German license for CINV combination therapy

Long-term data presented on LB-03002 in children with growth hormone deficiency

PolyMedix commences new study of PMX-60056

Denosumab shows long-term safety and efficacy in postmenopausal osteoporosis

Nippon Shinyaku synthesizes vitamin D3 antedrug

New PPAR-gamma agonists synthesized in Japan

Bayer Schering Pharma prepares novel diagnostics

Scientists at Pulmagen Therapeutics disclose new HLE inhibitors

Sunesis begins phase I trial of MLN-2480

Treatment begins in phase III PI-88 study

Ampio Pharmaceuticals announces promising data from Zertane extension study

Probiodrug presents new glutaminyl-peptide cyclotransferase inhibitors

Novel protein kinase inhibitors for cancer claimed by OSI

NIH selects Afraxis for TRND program on PAK biology

Promising phase I data on V-158866

Treatment begins in phase I trial of MicroDose Therapeutx candidate for RSV infection

Takeda files for approval of TAK-085 in Japan

Enrollment completed in Rexahn Pharmaceuticals' phase II Archexin trial

Chelsea Therapeutics submits NDA in U.S. for Northera

FDA accepts Talon Therapeutics' Marqibo NDA for filing

Cell Therapeutics completes assessment required for pixantrone NDA

Onyx Pharmaceuticals completes carfilzomib NDA submission

Transcept Pharmaceuticals resubmits Intermezzo NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...